The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

Imaging studies of more than 27,000 adults link a healthier thymus on CT scans with a longer life and lower risks of ...

Penn Engineers have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors. The particle delivers both mRNA that ...

MARCH 18, 2026, NEW YORK - The immune system's killer T cells do a commendable job of detecting and destroying cancer cells.

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea’s proprietary in vivo CAR T platformPeer-reviewed publication ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

Researchers developed an implant that boosts immune cell activity, enabling stronger, longer-lasting cancer responses in both ...

The powerful gene-editing technique CRISPR–Cas9 might offer a way to make safer, more effective cancer-fighting immune cells ...

For years, one of the most powerful weapons against certain blood cancers, called CAR-T cell therapy, has required an ...

A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...